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Background: Patients with type 2 diabetes (T2DM) are at risk of long-term vascular 
  complications. In trials, exenatide once weekly (ExQW), a GLP-1R agonist, improved glycemia, 
weight, blood pressure (BP), and lipids in patients with T2DM. We simulated potential effects 
of ExQW on vascular complications, survival, and medical costs over 20 years versus standard 
therapies.
Patients and methods: The Archimedes model was used to assess outcomes for ∼25,000 vir-
tual patients with T2DM (NHANES 1999–2006 [metformin ± sulfonylureas, age 57 years, body 
mass index 33 kg/m2, weight 94 kg, duration T2DM 9 years, hemoglobin A1c [A1C] 8.1%]). The 
effects of three treatment strategies were modeled and compared to moderate-adherence insulin 
therapy: advancement to high-adherence insulin at A1C $ 8% (treat to target A1C , 7%) and 
addition of pioglitazone (PIO) or ExQW from simulation start. ExQW effects on A1C, weight, 
BP, and lipids were modeled from clinical trial data. Costs, inflated to represent 2010 $US, were 
derived from Medicare data, Drugstore.com, and publications. As ExQW was investigational, 
we omitted ExQW, PIO, and insulin pharmacy costs.
Results: By year 1, ExQW treatment decreased A1C (∼1.5%), weight (∼2 kg), and systolic BP 
(∼5 mmHg). PIO and high-adherence insulin decreased A1C by ∼1%, increased weight, and did 
not affect systolic BP. After 20 years, A1C was ∼7% with all strategies. ExQW decreased rates 
of cardiovascular and microvascular complications more than PIO or high-adherence insulin 
versus moderate-adherence insulin. Over 20 years, ExQW treatment resulted in increased 
quality-adjusted life-years (QALYs) of ∼0.3 years/person and cost savings of $469/life-year 
versus moderate adherence insulin. For PIO or high-adherence insulin, QALYs were virtually 
unchanged, and costs/life-year versus moderate-adherence insulin increased by $69 and $87, 
respectively.
Conclusions: This long-term simulation demonstrated that ExQW treatment may decrease 
rates of cardiovascular and some microvascular complications of T2DM. Increased QALYs, 
and decreased costs were also projected.
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Background
The incidence of diabetes and associated health problems continues to increase in the 
United States.1,2 In 2010, approximately 25.6 million adults, or 11.3% of the adult 
(age $ 20 years) population in the United States had some form of diabetes, diag-
nosed or otherwise; 90% to 95% of the cases were type 2 diabetes mellitus (T2DM).3 
These patients are at long-term risk of cardiovascular events such as coronary heart 
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disease (CHD), myocardial infarction (MI), and stroke and 
of microvascular complications such as renal disease, retinal 
disease potentially leading to blindness, and lower extremity 
ulcerations that may result in amputation.3
Despite clear guidelines to help correct and maintain good 
glycemic control4,5 and a wide variety of antihyperglycemic 
therapies, most patients with diabetes have difficulty achiev-
ing glycemic targets.6 Diabetes is commonly accompanied 
by several comorbidities such as obesity, dyslipidemia, and 
hypertension that also contribute to cardiovascular disease 
(CVD).7,8 Patients with T2DM are two to four times more 
likely to experience cardiovascular disease than those without 
T2DM.3 Approximately two-thirds of patients with diabetes 
have elevated blood pressure (BP $140/90), which also 
contributes to CVD.3 Ideally, a diabetes therapy should alle-
viate the symptoms of diabetes, reduce the risk of diabetes 
complications, and reduce associated morbidity, mortality, 
and costs.
Exenatide, the first antihyperglycemic agent in the 
  glucagon-like peptide-1 (GLP-1) receptor agonist class, 
improves glycemic control9,10 by enhancing glucose-depen-
dent secretion of insulin, suppressing appetite, inhibiting 
postprandial glucagon secretion, and slowing gastric emp-
tying.10,11 The twice-daily formulation (ExBID) is currently 
used to improve glycemic control in patients with T2DM. A 
once-weekly formulation (ExQW) is currently approved in 
the European Union and in the United States. In clinical stud-
ies, ExQW treatment resulted in reductions in hemoglobin 
A1c (A1C) and weight as well as in cardiovascular risk factors 
such as BP and lipids in patients with T2DM.12–15
In the absence of long-term data on the effects of ExQW, 
we used the Archimedes model to assess the potential effects 
of ExQW, pioglitazone (PIO), and high-adherence insulin 
compared to moderate-adherence insulin on the incidence 
of cardiovascular and microvascular outcomes, on life-years, 
and on costs over 20 years in a cohort of patients with T2DM 
derived from the National Health and Nutrition Examination 
Survey (NHANES) 1999–2006.
Patients and methods
Description of Archimedes model
The Archimedes model simulates human physiology, disease 
progression, and health care delivery using an integrated 
model to describe the interactions of diseases, disease com-
plications, various treatments, and health care guidelines as 
well as measures of quality of life and cost.16–19 Using differ-
ential equations maintains the continuous nature of biological 
variables, time, and their interactions. Diseases, and their 
respective treatments, are modeled at the clinical level. The 
model includes the effects of diabetes and other diseases, and 
incorporates patient and provider behaviors, office visits and 
hospital admissions, tests and treatments, care delivery pro-
tocols, performance and compliance, utilization, and costs. 
The model has been validated against a number of major 
clinical trials, including trials of diabetes management and 
treatment.16–19
Description of simulation strategies
We designed simulation strategies to follow four hypo-
thetical cohorts of patients with T2DM on background 
metformin ± sulfonylureas (SFU): (1) moderate-adherence 
insulin, (2) high-adherence insulin, and initiation at simula-
tion start of (3) PIO or (4) ExQW. All strategies treated to 
a target A1C of 7%, but insulin was not initiated until A1C 
reached 8%. All strategies were identical with respect to 
general patient care guidelines and treatment goals, and 
concomitant diabetes treatments. Finally, all strategies 
maintained metformin therapy throughout the course of the 
20-year simulation, and terminated SFU treatment when insu-
lin was initiated. Adherence to insulin was set to 76% in the 
moderate-adherence insulin strategy,20,21 and to 100% in the 
high-adherence insulin strategy, to be more competitive with 
PIO and ExQW. Based on queries of the IMS Health database 
for PIO and ExBID, we assumed that 14% of patients treated 
with PIO and 21% of patients treated with ExQW would 
remain on therapy after insulin was initiated.
The simulation population was derived from NHANES 
1999–200622 and was reflective of patients with T2DM who 
had an A1C of 7%–11%, were 18–80 years old, were cur-
rently taking metformin with or without concomitant SFU, 
did not use insulin, and did not have end-stage renal disease. 
The simulation was run for 20 years with results reported 
annually; results at 5, 10, and 20 years are reported here.
Outcomes
The primary outcome of the four simulation strategies 
was their effect on prevention or delay of long-term 
cardiovascular disease and other diabetic complications. 
We also directly examined the impact on short-term (1-year) 
biomarker changes (eg, A1C, BP, lipids, weight) for each 
treatment strategy to ensure that data from the simulated 
and actual clinical trial populations were not substantially 
different. Cardiovascular disease outcomes included major 
adverse cardiovascular events (MACE- a composite 
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measure including MI, stroke, and CHD death), and 
individual measures of MI, stroke, CHD death, and con-
gestive heart failure (CHF). Microvascular complications 
of diabetes included macroalbuminuria, end-stage renal 
disease (ESRD), macular edema, blindness, foot ulcer, 
and lower extremity amputation. All-cause death was also 
assessed.
Other outcomes included life-years (LYs), quality-
adjusted LYs (QALYs), direct medical costs, and numbers 
needed-to-treat (NNT). The cost of health outcomes included 
the medical costs of hospital admissions, doctors’ visits, 
procedures, medications other than study medications, and 
tests. Inpatient, outpatient, ambulatory, and treatment costs 
were based primarily on Medicare charges. All costs were 
inflated to represent 2010 US dollars. Cost effectiveness 
was calculated using standard methods.23 Since ExQW 
was investigational at the time of this analysis, the costs of 
insulin, PIO, and ExQW treatments were not included in the 
calculations and we conducted a cost consequence analysis. 
QALYs were calculated as the sum of time spent in various 
health states, discounted by disutility scores associated with 
the state’s corresponding conditions.24 The model scanned 
each (virtual) patient’s medical record and applied disutil-
ity discounts associated with specific diagnoses. NNT was 
computed as in Altman et al.25
ExQW model
The ExQW model was constructed using data from four 
phase III clinical trials of ExQW treatment. Data from 
DURATION-1 (104 weeks),14 DURATION-2 (52 weeks),15 
DURATION-3 (26 weeks),12 and DURATION-5 (26 weeks)13 
were used to quantify the effect of ExQW on A1C, weight, 
BP, total cholesterol (TC), and triglycerides (TG). Data 
points from the trials for a given variable (eg, weight) were 
pooled, and the locally-weighted scatterplot smoothing 
(LOESS) technique was used to fit contours to the resulting 
aggregation, modeling the change from baseline as a 
function of time and baseline value.26 In the absence of 
long-term clinical trial data at the time of data analysis, 
no further change in effect was modeled for ExQW after 
2 years, although the simulation included changes resulting 
from natural biomarker drift (eg, the effect of aging) and 
changes due to background patient care. Additionally, no 
direct effects on disease progression were modeled, just the 
effect of treatment on A1C, weight, BP, TC, and TG. For 
initial biomarkers values at normal levels, we assumed no 
effect of ExQW. Only ExQW was newly modeled for this 
work; models for PIO and insulin were already included in 
the Archimedes model.18
Results
Demographics, biomarker trajectories, 
and medication use
The simulated population was derived from NHANES in 
order to create a sample representative of patients meet-
ing the inclusion criteria (18–80 years old, T2DM, A1C 
7%–11%, currently using metformin ± SFU, not yet taking 
insulin). Generally, patients in the simulation were similar 
to those in the ExQW trials, differing by ,1 standard devia-
tion (Table 1).
 An initial assessment of biomarkers after 1 year of simu-
lated treatment for all strategies showed results that were 
in line with expectations. A1C decreased by ∼1% in PIO- 
and high-adherence insulin-treated patients and decreased 
by ∼1.5% in ExQW-treated patients. Patients treated with 
both insulin strategies and PIO experienced modest initial 
increases in weight while ExQW-treated patients experienced 
a reduction in weight of ∼2 kg. In the PIO and high-adherence 
insulin strategies there was little change in systolic BP (SBP), 
while the ExQW strategy decreased SBP by ∼5 mmHg. 
Changes in lipid profiles were observed primarily in PIO- and 
ExQW-treated patients. In PIO-treated patients, TG decreased 
by 16.3% and TC, high-density lipoproteins (HDL), and 
low-density lipoproteins (LDL) increased by 3.4%, 12.4%, 
and 6.5%, respectively. In ExQW-treated patients, decreases 
of 6.5%, 15.8%, and 6.2% were observed in TC, TG, and 
LDL, respectively; HDL did not change.
At the end of the 20-year simulation, A1C was ∼7% for 
all three treatment strategies, which was an expected outcome 
given the treat-to-target aspect of the simulations (Figure 1A). 
After changes in the first year, weight gradually decreased 
and SBP gradually increased with all treatment strategies 
due to the natural progression of aging (Figure 1B and C). 
After initial changes, LDL gradually decreased in all treat-
ment strategies; HDL and TG remained fairly constant. Total 
cholesterol also gradually declined in all treatment strategies 
over the simulation period, with the greatest decrease after 
20 years seen in EQW-treated patients (Figure 2).
As the simulation progressed, patients’ use of insulin and 
other background medications changed based on the level of 
control for a given biomarker. In all strategies, as patients 
reached an A1C of 8%, insulin treatment was initiated. By 
the end of the 20-year simulation, 55%, 82%, 29%, and 21% 
of patients in the moderate-adherence insulin, high-adherence 
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insulin, PIO, and ExQW arms, respectively, had initiated 
insulin use. The marked drop in the percentage of patients 
transitioning to insulin observed in the PIO and ExQW arms 
provided an indication of the effect of these agents on glyce-
mic control. The percentage of patients using antihyperten-
sive agents and statins increased over time for all treatment 
strategies (∼20% to 22% antihypertensives, ∼18% to 25% 
statins), but the increase in patients using these medications 
was slightly lower in ExQW-treated patients (∼20% antihy-
pertensives, ∼18% statins). The decreased use of antihyper-
tensives in ExQW-treated patients was due to the decrease in 
SBP. Statin use also mirrored the effect of treatments on LDL, 
increasing in PIO-treated patients and decreasing slightly in 
ExQW-treated patients relative to the insulin arms.
Effect on health outcomes
The effect of the four strategies on biomarkers translated 
to beneficial changes in overall long-term clinical health 
outcomes in the model. The event rates for MACE, 
components of MACE, and microvascular complications 
commonly associated with diabetes generally decreased 
for the three treatment arms relative to moderate-adherence 
insulin (Figure 3). For most health outcomes, ExQW 
decreased the event rate to a greater degree than did PIO 
and high-adherence insulin by virtue of its greater effect on 
A1C, weight, BP, and lipids. All-cause death decreased for all 
treatments compared to moderate-adherence insulin, but was 
statistically significant only for patients treated with ExQW 
(Figure 3). These decreases were pronounced at 20 years and 
most were seen as early as 5 and 10 years.
Effects on LYs, QALYs, and costs
At 5, 10, and 20 years, ExQW was associated with increased 
LYs and lower direct medical costs than moderate-adherence 
insulin, high-adherence insulin, and PIO strategies. Costs 
calculated did not include the cost of the treatments insulin, 
PIO, and ExQW. These differences resulted in an average 
cost/LY benefit of over $400 ($409–$469) relative to control 
(Table 2).
 ExQW increased QALYs more than all other treat-
ments, an effect that was observed at 5 years and continued 
to 20 years. After 20 years of treatment, QALYs were 
13.72, 13.52, 13.46, and 13.44 per initial person for ExQW, 
high-adherence insulin, PIO and moderate-adherence 
insulin, respectively. Over 20 years, these changes trans-
lated into increases in QALYs for ExQW-treated patients 
of ∼3 months versus moderate-adherence insulin and 
PIO, and of ∼2.4 months versus high-adherence insulin 
(Figure 4).
Numbers needed-to-treat (NNTs)
ExQW required substantially fewer patients to be treated to 
avoid a single event than the high-adherence insulin and PIO 
strategies relative to moderate-adherence insulin (Table 3).
Table 1 Baseline characteristics of the simulation and DURATION trials populations
Simulation (SD) NHANESa DURATION clinical trials – ExQW arm
Study 1 Study 2 Study 3 Study 5
Sample size 24,878 303 148 160 233 123
Age, year 57.3 (12.5) 58 55 52 58 55
Gender, % male 51.3 46 55 56 52 55
BMI, kg/m2 33.1 (6.5) 33 35 32 32 33
Weight, kg 93.6 (21.3) 94 102 89 91 94
SBP, mmHg 127.7 (16.0) 132 128 126 135 128
DBP, mmHg 72.3 (11.9) 71 78 – 81 77
FPG, mg/dL 177.3 (33.5) 176 173 166 178 168
A1C, % 8.1 (0.9) 8.1 8.3 8.6 8.3 8.4
TC, mg/dL 198.4 (47.8) 195 174 174 186 196
HDL, mg/dL 48.2 (14.7) 44 44 42.5 46 46
LDL, mg/dL 111.1 (40.4) 107 92 104 104 120
TG, mg/dL 197.6 (146.2) 225 167b 168b 164b 158b
Creatinine, mg/dL 0.89 (0.20) 0.83 – – – –
Diabetes duration, year 9.0 (8.4) 9.6 7 6 8 7
Smokers, % 19.1 18.1 – – – –
History of myocardial infarction, % 7.1 8.1 – – – –
History of stroke, % 3.4 5.4 – – – –
History of CHF, % 4.8 4.7 – – – –
Notes: aSubjects fulfilling simulation inclusion/exclusion criteria; bdata are geometric, rather than arithmetic, means.
Abbreviations:  BMI,  body  mass  index;  CHF,  congestive  heart  failure;  DBP,  diastolic  blood  pressure;  FPG,  fasting  plasma  glucose;  HDL,  high-density  lipoproteins;  LDL, 
low-density lipoproteins; SBP, systolic blood pressure; SD, standard deviation; TC, total cholesterol; TG, triglycerides; creatinine sample is serum. 
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Discussion
Modeling of health and economic outcomes allows an 
estimation of potential effects of new treatments with 
insufficient long-term data. This simulation provided evidence 
for the effectiveness of ExQW compared with insulin 
or PIO for preventing the cardiovascular complications, 
microvascular complications, and death associated with 
diabetes over 20 years of treatment.
Biomarkers such as A1C, weight, blood pressure, and 
lipids are associated with poor long-term cardiovascular 
health if not kept within normal ranges. Clinical trial data 
have shown that ExQW decreases these biomarkers, but the 
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data are short-term and limited to controlled clinical trial 
settings. Our simulation indicated that the effect of ExQW 
on improved glycemic control and cardiovascular biomark-
ers was associated with reduced cardiovascular event rates 
over 20 years. However, we note that the existence of a 
clinically-significant and positive relationship between 
glycemic control and cardiovascular event rates has been 
variable in a number of prospective trials.27,28 The MACE 
composite event rate, including MI, stroke, and CHD death, 
decreased with all treatments compared with moderate-
adherence insulin, but patients treated with ExQW achieved 
the lowest rates.
All treatments in the simulation improved glycemic con-
trol but, as with cardiovascular risk factors, after 20 years, 
ExQW treatment reduced the risk of microvascular com-
plications more than did high-adherence insulin or PIO. 
By design, all patients in the model were treated to target 
(A1C = 7%), and all strategies reduced the microvascular 
complications of diabetes. Many of these microvascular 
complications are also subject to the effects of weight and 
blood pressure. For example, macroalbuminuria, a precur-
sor of serious renal complications, is affected by glycemic 
control as well as blood pressure.29,30 ExQW reduced 
macroalbuminuria by ∼40%, while high-adherence insulin 
and PIO reduced macroalbuminuria event rates by ∼16 and 
15%, respectively. Development of two earlier-stage retinal 
complications of diabetes, proliferative diabetic retinopa-
thy (PDR, data not shown) and macular edema, is governed 
to a large extent by glycemic control and blood pressure.29,30 
The event rates of PDR and macular edema were decreased 
more in patients treated with ExQW than in patients 
treated with PIO and high-adherence insulin.   However, 
the treatment strategies had only a small and similar effect 
on the very late stage complication of total blindness. 
Lower extremity amputation, driven by A1C, was similar 
across all therapies compared with moderate-adherence 
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Figure 3 Changes relative to moderate-adherence insulin in Kaplan-Meier event rates of cardiovascular and microvascular complications of diabetes after 20 years of 
simulated treatment with high-adherence insulin, PIO, and ExQW.
Notes: Negative values represent improvements over moderate-adherence insulin.  All differences are statistically significant at the 5% level with these exceptions: for 
myocardial infarction and coronary heart disease death, PIO and ExQW are not significantly different; for stroke, bilateral blindness, and all-cause death, high-adherence 
insulin and PIO do not significantly differ from moderate-adherence insulin; for congestive heart failure, high-adherence insulin and ExQW do not differ significantly from 
moderate-adherence insulin; for macroalbuminuria, high-adherence insulin and PIO do not significantly differ; for ESRD, PIO does not significantly differ from high-adherence 
insulin, nor from moderate-adherence insulin; for macular edema, PIO does not significantly differ from moderate -adherence insulin; for foot ulcer and lower extremity 
amputation, high-adherence insulin, PIO, and ExQW do not differ amongst themselves, but all are significantly different from moderate-adherence insulin.
Abbreviations: ExQW, exenatide once weekly; PIO, pioglitazone.
Table 2 Total life-years and costs (undiscounted) per initial person for high-adherence insulin, PIO, and ExQW vs moderate-adherence 
insulin after 5, 10, and 20 years of treatment
Simulation strategy Total life years Total costs Difference vs moderate-adherence insulin
US$ 2010 Life years Cost Cost/life years
5 years
Moderate-adherence insulin 4.77 $36,568 – – –
High-adherence insulin 4.77 $36,861 0.004 $293 $56
PIO 4.76 $36,153 -0.003 -$415 -$82
ExQW 4.78 $34,739 0.016 -$1,829 -$409
10 years
Moderate-adherence insulin 9.03 $75,703 – –
High-adherence insulin 9.05 $76,492 0.016 $789 $73
PIO 9.03 $75,292 -0.005 -$411 -$41
ExQW 9.10 $72,104 0.064 -$3,600 -$455
20 years
Moderate-adherence insulin 15.80 $154,087 – –
High-adherence insulin 15.87 $156,193 0.075 $2,106 $87
PIO 15.81 $155,281 0.010 $1,195 $69
ExQW 16.06 $149,137 0.264 -$4,950 -$469
Notes: Moderate-adherence insulin, treatment with insulin, initiated once glycemic control lapsed, usually when A1C .8.0%, with adherence set to 76%.
Abbreviations: ExQW, exenatide once weekly; PIO, pioglitazone
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insulin (∼15% reduction), since all therapies treated to 
an A1C target of 7%. Finally, treatment with ExQW had 
a small, but significant, improvement over treatment 
with PIO or high-adherence insulin in reducing all-cause 
death.
The improvements in health outcomes had substantial 
economic benefits. After 20 years of treatment, QALYs 
increased and total medical costs decreased for patients 
treated with ExQW compared to all other strategies. These 
improvements with ExQW treatment were observed after 
5 years and increased as the simulation progressed. Cost sav-
ings were also observed with PIO treatment at 5 and 10 years, 
but were markedly less than for ExQW, and the savings 
disappeared entirely by simulation end.
Limitations and assumptions
These findings were based on a mathematical model and as 
such were subject to the assumptions used to create it. The 
ExQW model was derived from four clinical trials, each with 
limited data, and assumed that the effects of ExQW treatment 
would remain constant after year 2, that ExQW treatment 
would continue indefinitely unless advancement to insulin 
occurred, and that there were no adverse effects associated 
with ExQW treatment. The adverse effects that were modeled 
included hypoglycemia for insulin and SFU treatment and 
CHF for PIO treatment, both well-documented for the respec-
tive treatments. Patients were assumed to be 100% compliant 
to insulin, PIO, and ExQW in the high-adherence insulin, PIO, 
and ExQW treatment strategies, respectively, a less than real-
istic scenario. However, effects for more realistic compliance 
levels can be estimated by interpolating results between the 
moderate-adherence insulin and the other treatment arms. The 
simulation model did include the cost of treatment for diseases/
conditions such as high blood pressure and high cholesterol; 
it did not include any treatment costs for insulin, PIO, and 
ExQW. Finally, the impact of known or suspected biomarkers 
for cardiovascular and microvascular complications such as 
measures of inflammation, oxidation, or fat-derived cytokines 
and the effects of each of the glucose-lowering agents on these 
markers were not included in the model.
Conclusion
The simulation of ExQW treatment in patients with T2DM 
for 20 years indicates that the treatment may decrease the 
complications associated with the morbidity and mortality 
Table 3 Numbers needed-to-treat versus moderate-adherence insulin to avoid a single cardiovascular event
Outcome Treatment strategy Number needed-to-treat versus  
moderate-adherence insulin
5 years 10 years 20 years
MACE composite High-adherence insulin 341 128 91
PIO 149 59 43
ExQW 74 38 29
Myocardial infarction High-adherence insulin 345 126 84
PIO 142 58 38
ExQW 94 47 33
Stroke High-adherence insulin .1,000 .1,000 .1,000
PIO .1,000 818 413
ExQW 295 142 85
Coronary heart disease death High-adherence insulin .1,000 429 236
PIO .1,000 257 116
ExQW 407 197 95
Abbreviations: MACE, major adverse cardiovascular event and is a composite measure including myocardial infarction, stroke, and coronary heart disease death; moderate 
adherence insulin, treatment with insulin, initiated once glycemic control lapsed, usually when A1C . 8.0%, with adherence set to 76%.
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1000 simulated patients.
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of T2DM, including MACE and many microvascular 
  complications. ExQW treatment was also associated with 
a decrease in the cost of management of diabetes and its 
complications and an increase in QALYs. Simulations using 
ExQW data gathered beyond 2 years and incorporating 
adverse event data will further refine these observations. 
Validation through long-term trials such as the Exenatide 
Study of Cardiovascular Event Lowering (EXSCEL) trial 
(NCT01144338) is also needed.
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